Anavar Bloodwork Guide: What to Test Before, During, and After Your Cycle and How to Read Every Marker

Running Anavar without bloodwork is the equivalent of driving without a dashboard. You have no idea what your liver enzymes, lipid panel, hormone levels, or haematocrit are doing until symptoms appear, and by the time symptoms appear, the damage is already well advanced. Proper Anavar bloodwork is not optional. It is the only tool that converts an unmonitored experiment into a managed protocol with defined entry criteria, mid-cycle checkpoints, and post-cycle confirmation of recovery. At Hemi Pharma UK, we consider informed monitoring as important as product purity, which is why every batch undergoes independent Janoshik Analytical testing before reaching the UK market.

In 2024, the British Journal of General Practice published the first UK clinical practice guideline specifically addressing blood testing for patients using androgenic anabolic steroids. That guideline, along with the specialist protocols from the Spaarne Gasthuis AAS clinic in the Netherlands and published harm-reduction reviews, provides a clinical framework that this article translates into a practical, Anavar-specific monitoring schedule. Every marker recommended below has a specific reason for inclusion, a defined normal range, a threshold that should trigger concern, and a threshold that should trigger cessation.

What Should Your Baseline Anavar Bloodwork Panel Include Before the First Dose?

Your baseline panel establishes the reference point against which every subsequent test is compared. Without it, you cannot determine whether a mid-cycle value represents a meaningful change or simply reflects your pre-existing physiology. The following markers should be drawn fasted, in the morning (before 10am), at least 48 hours after your last heavy training session to minimise exercise-induced transaminase elevation.

Hormonal Panel

Total testosterone, free testosterone (or calculated from albumin and SHBG), SHBG, oestradiol (E2), LH, and FSH. These six markers map your endocrine baseline completely. Total and free testosterone establish your starting point for measuring suppression. SHBG is critical because oxandrolone suppresses it dramatically, which amplifies free testosterone transiently before the HPTA crash. LH and FSH confirm your pituitary is functioning normally before you introduce an exogenous androgen. Oestradiol matters because Anavar does not aromatise, so any decline in E2 during the cycle reflects reduced substrate (falling testosterone) rather than a direct effect of oxandrolone.

Liver Function

ALT, AST, GGT, and bilirubin. The 2024 BJGP clinical practice guideline for primary care physicians managing AAS-using patients identifies liver function tests as a core component of the monitoring panel (BJGP, 2024). ALT and AST are the standard transaminases, but they are not liver-specific in isolation. Skeletal muscle damage from resistance training also elevates both markers. GGT is the differentiator: if ALT and AST are elevated but GGT is normal, the source is almost certainly muscular, not hepatic. If GGT is also elevated, the liver is involved. Bilirubin provides a secondary check on hepatic conjugation capacity.

Lipid Panel

Total cholesterol, HDL, LDL (calculated or direct), and triglycerides. As covered in our dedicated Anavar and cholesterol article, HDL suppression is the most clinically significant lipid effect of oxandrolone, and it begins within the first week. Your baseline HDL value determines how much headroom you have before reaching critically low levels.

Haematology

Full blood count with haematocrit and haemoglobin. Anabolic steroids stimulate erythropoiesis, increasing red blood cell mass. The BJGP guideline specifies a haematocrit threshold of 0.52 (52%) for males, above which cessation of all anabolic steroids and repeat analysis is advised. For extremely raised haematocrit above 0.60 (60%), the guideline recommends urgent haematology referral (BJGP, 2024). Oxandrolone produces less erythrocytosis than injectable testosterone or nandrolone, but the risk is not zero, particularly in users stacking with a testosterone base.

Kidney Function

Creatinine, eGFR, and urea. A 2025 forensic review in Frontiers in Cardiovascular Medicine reported that albuminuria was documented in 16% of AAS users and elevated serum creatinine was a consistent finding in cases of kidney injury associated with steroid use (Di Fazio et al., 2025). Creatinine has a known confound in AAS users: increased muscle mass raises creatinine production independently of kidney function. If creatinine is elevated, eGFR should be interpreted cautiously, and cystatin C (if available) provides a muscle-mass-independent measure of glomerular filtration.

Metabolic

Fasting glucose and HbA1c. The BJGP guideline specifically recommends HbA1c monitoring in patients using human growth hormone, but fasting glucose is relevant for all AAS users because oxandrolone can alter insulin sensitivity. Establishing a baseline allows detection of any metabolic shift during the cycle.

Why Does the UK Clinical Guideline Recommend These Specific Thresholds for Steroid Users?

The 2024 BJGP guideline represents a significant development because it is the first formal UK primary care guideline to address blood testing in active AAS users. Previously, clinicians had no standardised protocol and often either refused to engage with AAS-using patients or ran ad hoc panels with no defined action thresholds.

The guideline was informed by specialist AAS clinics, including the Spaarne Gasthuis outpatient clinic in the Netherlands, described by Smit and de Ronde (2018) in the Netherlands Journal of Medicine. That clinic, one of the first dedicated AAS user clinics in the world, developed monitoring protocols based on the most commonly observed adverse effects in their patient population (de Ronde & Smit, 2020). Their approach prioritises practical harm reduction: identifying the markers most likely to detect clinically significant problems early enough to intervene.

The BJGP guideline distils this into a decision tree. For liver function: if ALT is below 3 times the upper limit of normal (3x ULN), repeat testing 10 to 14 days after cessation of heavy weightlifting. If ALT normalises, the elevation was muscular, not hepatic. If it remains elevated, follow the standard raised ALT clinical pathway. For haematocrit: if above 0.52, advise cessation and repeat. If above 0.60, urgent haematology referral. For lipids: document dyslipidaemia and advise on increased cardiovascular risk. These thresholds are not arbitrary. They are drawn from the clinical experience of the specialist AAS clinics and the established medical literature on AAS-associated adverse effects.

What Anavar Bloodwork Markers Change at Week 4 and What Do They Mean?

Week 4 is the optimal mid-cycle checkpoint for a standard 6 to 8 week Anavar cycle. By this point, oxandrolone has reached steady-state concentrations (which occurs within 2 to 3 days given the 9-hour half-life, but organ-level effects take longer to manifest fully), SHBG suppression is well established, and hepatic lipase upregulation has had time to produce measurable HDL changes.

The expected mid-cycle Anavar bloodwork pattern in a male running 40mg to 60mg daily alongside a testosterone base of 100mg to 150mg weekly looks approximately like this:

Total testosterone will reflect your exogenous dose, typically in the 600 to 1200 ng/dL range depending on the testosterone ester and dose. SHBG will be suppressed to single digits or low teens (nmol/L), which means free testosterone will be disproportionately elevated relative to total testosterone. LH and FSH will be near zero, confirming full HPTA suppression. Oestradiol should be in the normal male range if aromatisation from the testosterone base is adequate; if it is low (below 20 pg/mL), the testosterone dose may be insufficient or an aromatase inhibitor like anastrozole is being over-dosed.

HDL will have dropped significantly, often to the 20 to 35 mg/dL range. LDL will have increased modestly. ALT and AST may be mildly elevated (1.5x to 2.5x ULN is typical at moderate Anavar doses), but remember to check GGT to differentiate hepatic from muscular sources. Haematocrit may have increased by 1 to 3 percentage points from baseline, though this is more pronounced with the injectable testosterone component than with oxandrolone itself.

A 2020 survey of 2,385 men using AAS by Bonnecaze et al. found that the majority of users conducted some form of self-directed bloodwork, but many lacked the clinical knowledge to interpret abnormal results or determine when values warranted discontinuation (Bonnecaze et al., 2020). The value of the monitoring protocol is not just in the numbers. It is in knowing what those numbers mean and what to do about them.

How Do You Separate Liver Damage From Muscle Damage on Anavar Bloodwork?

This is one of the most common sources of unnecessary panic among Anavar users, and it has a straightforward clinical solution. Both ALT and AST are present in skeletal muscle tissue as well as hepatocytes. Intense resistance training, particularly eccentric-heavy work, can elevate both enzymes without any liver involvement whatsoever. A user who trains legs hard, gets bloodwork 24 hours later, and sees AST at 80 U/L and ALT at 65 U/L may assume their liver is failing when the elevation is entirely muscular in origin.

The BJGP guideline addresses this directly. It recommends that if ALT is below 3x ULN, the test should be repeated 10 to 14 days after cessation of heavy exercise. If the repeat value has normalised, the source was muscular. The additional differentiator is GGT (gamma-glutamyl transferase). GGT is not meaningfully present in skeletal muscle. If ALT and AST are elevated but GGT is normal, the elevation is almost certainly from training, not from oxandrolone hepatotoxicity. If GGT is also elevated (particularly above 3x ULN), the liver is the likely source, and further investigation is warranted.

De Ronde and Smit (2020) noted in their endocrinologist guide that the mild ALT and AST elevations frequently encountered in AAS-using patients are “mostly” attributable to exercise-induced muscle damage rather than true hepatotoxicity. This does not mean liver damage cannot occur. It means that the interpretation of transaminases in this population requires the additional context of exercise history and GGT results. Without GGT, you cannot make the distinction reliably.

What Does Post-Cycle Anavar Bloodwork Tell You About Recovery?

Post-cycle bloodwork serves two purposes: confirming that your organ function markers have returned to safe ranges, and confirming that your HPTA has recovered endogenous testosterone production (or is on track to do so with PCT support).

The optimal timing for post-cycle Anavar bloodwork depends on whether you are running PCT. If you are using tamoxifen or clomiphene citrate for PCT, draw blood 2 to 4 weeks after completing the PCT protocol. Testing during PCT will show artificially elevated LH (from the SERM’s action at the pituitary) and may not reflect true recovered function. Testing after PCT allows you to see whether endogenous production has been successfully restarted without pharmacological support.

The markers you are looking for at this stage: total testosterone should be trending toward or at your pre-cycle baseline. LH and FSH should be detectable and rising, confirming pituitary recovery. SHBG should be recovering from the suppressed levels seen during the cycle. HDL should be trending upward. Liver enzymes should have normalised. Haematocrit should be at or near baseline.

If testosterone remains below 300 ng/dL with LH below 2 IU/L at 8 weeks post-PCT, recovery is stalled, and clinical evaluation is warranted. The harm-reduction review by Goldman et al. (2021) in the Journal of General Internal Medicine emphasised that continued close clinical surveillance is recommended even in users who wish to continue AAS use, specifically because ongoing monitoring allows detection of adverse effects that may not produce symptoms until they are advanced (Goldman et al., 2021).

What Red-Flag Values on Anavar Bloodwork Should Trigger Immediate Action?

Not all abnormal results are equally urgent. Some values warrant monitoring and potential dose reduction. Others warrant immediate cessation. The following thresholds, drawn from the BJGP guideline and specialist AAS clinic protocols, define the boundary between manageable deviation and clinical emergency:

Stop and seek medical evaluation immediately

Haematocrit above 0.54 (54%): risk of thrombosis, stroke, and cardiovascular events increases substantially. The BJGP guideline sets the cessation threshold at 0.52 for routine management and urgent referral at 0.60, but most specialist protocols recommend intervention at 0.54 for active users. ALT or AST above 5x ULN with concurrent GGT elevation: this pattern indicates genuine hepatotoxicity rather than exercise-induced elevation. Total bilirubin rising alongside elevated transaminases: suggests biliary involvement or more significant hepatic compromise. Severe chest pain, persistent headaches, or visual disturbances alongside any abnormal bloodwork: these symptoms in the context of AAS use warrant emergency evaluation.

Reduce dose or discontinue the oral component

HDL below 25 mg/dL: the cardiovascular risk at this level is substantial, and continuing the oral component extends the duration of exposure. ALT above 3x ULN with GGT also elevated: the BJGP guideline recommends following the standard raised ALT pathway at this point. Creatinine rising above your personal baseline by more than 20% without an obvious explanation (dehydration, recent creatine loading): warrants investigation of renal function.

Monitor closely and repeat in 2 weeks

ALT 1.5x to 3x ULN with normal GGT: likely muscular. Repeat after 10 to 14 days without heavy training. HDL between 25 and 35 mg/dL: concerning but manageable over a short cycle. Ensure cardiovascular exercise is maintained. Haematocrit between 0.50 and 0.54: trending toward the danger zone. Hydration status should be optimised and the value rechecked.

Frequently Asked Questions

How much does a full Anavar bloodwork panel cost in the UK?

Private blood testing in the UK through services such as Medichecks or Forth typically costs between £100 and £200 for a comprehensive panel covering hormones, liver function, lipids, haematology, and kidney markers. NHS GPs can order these tests under the 2024 BJGP guideline framework if you disclose AAS use, though availability varies by practice. The cost of three panels (baseline, mid-cycle, post-PCT) across a single Anavar cycle is approximately £300 to £600. This is a fraction of the cost of the compounds themselves and provides objective data that no amount of subjective “feeling fine” can replace.

Can I just test liver enzymes and skip the rest?

No. Liver enzymes are important, but they are not the most clinically significant marker during an Anavar cycle. HDL cholesterol suppression is the most dangerous short-term effect of oxandrolone, and it produces no symptoms until cardiovascular damage has occurred. Hormonal markers confirm HPTA suppression and guide PCT timing. Haematocrit detects erythrocytosis before it produces thrombotic events. Testing only liver enzymes gives you a fraction of the picture and misses the markers most likely to cause harm.

Do I need to fast before Anavar bloodwork?

Yes. A 10 to 12 hour fast is required for accurate lipid and glucose measurements. Schedule your blood draw for first thing in the morning. Testosterone levels are also highest in the morning (following the circadian rhythm of pulsatile LH release), so morning sampling provides the most standardised hormonal values. Avoid heavy training for at least 48 hours before the draw to minimise exercise-induced transaminase elevation that can confuse the liver function interpretation.

What is the single most important marker on Anavar bloodwork?

If you could only test one marker, HDL cholesterol would provide the most actionable information. It is the marker most dramatically affected by oxandrolone, the one most closely linked to cardiovascular risk during active use, and the one that most users underestimate. A mid-cycle HDL below 25 mg/dL is a clear signal that the oral component should be shortened or discontinued. However, testing only one marker is never recommended. The value of Anavar bloodwork comes from the pattern across multiple systems, not from any single number in isolation.

Should I get bloodwork if I am only running Anavar for 4 weeks?

Yes. Even a 4-week cycle produces measurable HPTA suppression, significant HDL reduction, and potential liver enzyme changes. The Horwitz et al. (2019) study in the Journal of Internal Medicine demonstrated that AAS use is associated with increased morbidity across cardiovascular, thromboembolic, and hepatic systems regardless of cycle length (Horwitz et al., 2019). A shorter cycle reduces total exposure but does not eliminate the need for monitoring. At minimum, run a baseline panel before the first dose and a post-cycle panel 4 to 6 weeks after the last dose.